Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12448268 | 0.89 | PDE4B (0.35) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL25094200 | 0.89 | PDE4B (0.35) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL17660647 | 0.89 | PDE4B (0.35) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL23133949 | 0.86 | HTR4 (0.42) | PIK3CDSMN1; SMN2 | |
| SCHEMBL5268205 | 0.84 | MEN1 (0.36) | EPHX2SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL19322325 | 0.83 | PIK3CD (0.37) | PIK3CDCYP1A2TDP1RAB9AKCNQ3 | |
| SCHEMBL14403745 | 0.83 | EPHX2 (0.41) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL25143816 | 0.82 | MEN1 (0.43) | EPHX2MEN1ALDH1A1KMT2AKCNQ3 | |
| SCHEMBL12530792 | 0.82 | GAA (0.36) | MEN1ALDH1A1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL22473034 | 0.82 | PIK3CD (0.41) | PIK3CDEPHX2EPHX1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885EPHX2 1456/4885EPHX1 1290/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | PIK3CD 27/4885EPHX2 1868/4885EPHX1 1759/4885 |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | PIK3CD 3432/4885EPHX2 334/4885EPHX1 450/4885 |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | PIK3CD 1373/4885EPHX2 422/4885EPHX1 250/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | PIK3CD 632/4885EPHX2 2891/4885EPHX1 3853/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | PIK3CD 426/4885EPHX2 2641/4885EPHX1 1586/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PIK3CD 1373/4885EPHX2 422/4885EPHX1 250/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885EPHX2 1456/4885EPHX1 1290/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | PIK3CD 426/4885EPHX2 2641/4885EPHX1 1586/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | PIK3CD 1772/4885EPHX2 1256/4885EPHX1 604/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | PIK3CD 64/4885EPHX2 2974/4885EPHX1 2711/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | PIK3CD 3479/4885EPHX2 2760/4885EPHX1 545/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | PIK3CD 3166/4885EPHX2 337/4885EPHX1 410/4885 |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | PIK3CD 3374/4885EPHX2 807/4885EPHX1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.